CN103127413B - Pharmaceutical preparation for treating coronary diseases - Google Patents
Pharmaceutical preparation for treating coronary diseases Download PDFInfo
- Publication number
- CN103127413B CN103127413B CN201310076846.9A CN201310076846A CN103127413B CN 103127413 B CN103127413 B CN 103127413B CN 201310076846 A CN201310076846 A CN 201310076846A CN 103127413 B CN103127413 B CN 103127413B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- pharmaceutical preparation
- treatment
- grams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention discloses a pharmaceutical preparation for treating coronary diseases, and the pharmaceutical preparation is composed of the following bulk pharmaceutical chemicals in parts by weight: 20-30 parts of radix polygonati officinalis, 10-15 parts of cornus officinalis, 10-15 parts of uncaria rhynchophylla, 5-8 parts of fried spina date seeds,, 5-8 parts of platycodon grandiflorum, 20-30 parts of roots of straight ladybell, 30-40 parts of notoginseng, 25-35 parts of rhizoma ligustici wallichii, 15-30 parts of salvia miltiorrhiza, 10-15 parts of prepared rhizome of rehmannia, 10-20 parts of licorice roots, 10-20 parts of radix paeoniae alba, 5-15 parts of rhizoma imperatae, 20-35 parts of sangusis draconis, 15-25 parts of asarum, and 5-20 parts of humifuse euphorbia herbs. In the process of treatment, the pharmaceutical preparation is taken orally, one period of treatment lasts 10 days, the pharmaceutical preparation takes effect generally after one period of treatment, and after 2-3 periods of treatment, patients get better or are rehabilitated. The pharmaceutical preparation disclosed by the invention has the following advantages: 1, the pharmaceutical preparation is a pure natural Chinese herbal medicine, therefore, the pharmaceutical preparation is small in toxic and side effects and unique in therapeutic effect; and 2, the pharmaceutical preparation takes effect quickly and has an exact curative effect, and the clinical application of more than 600 patients verifies that the effective rate can reach 96.6%.
Description
Technical field
The present invention relates to a kind of pharmaceutical preparation for the treatment of coronary heart disease.
Background technology
Coronary heart disease (coronary artery heart disease, CHD) be called for short coronary heart disease, a kind of modal heart disease, refer to the myocardial dysfunction and (or) the organic disease that cause because of coronary stricture, blood supply insufficiency, therefore claim again ischemic cardiomyopathy (IHD).CHD is the result of multiple coronary artery disease, but coronary atherosclerosis accounts for absolutely large (95%-99%) majority of coronary heart disease, therefore, traditionally coronary heart disease is considered as to coronary atherosclerotic heart (coronary atherosclerotic heart disease) synonym.
Motherland's medical science thinks that primary disease main manifestations is deficiency in origin and excess in superficiality, simulataneous insufficiency and excessive, and its deficiency in origin can have yang blood and qi virtual loss, and mark is real is that the stagnation of QI, cold coagulation, expectorant are turbid, blood stasis, and again can be sick each other mutually, its pathogenesis is blockage of the cardiac vessels, and its sick position is taking the heart as main, and relevant with the dirty functional disorder of liver,spleen,kidney three.
Modern medicine is thought, coronary heart disease is due to coronary atherosclerosis, or thrombosis is attached on coronary blood tube wall and causes coronary stricture, reduce by coronary artery blood flow, when cardiac load increases suddenly, need blood volume to increase, exceed the compensatory capacity of coronary artery blood supply, or need blood volume not increase, but coronary spasm, reduce blood flow, or above-mentioned factor exists simultaneously, all can cause heart sharply, temporary transient ischemia, anoxia and angina pectoris occurs, while producing the direct factor of pain perception and may be due to myocardial ischemia-anoxemia, too much metabolite is as lactic acid, the acidic materials such as acetone acid and polypeptides matter, the centripetal fiber tip of autonomic nerve in cardiac stimulus, saving corresponding spinal cord segment through 1-5 Sympathetic nerve reaches brain and produces the pain sensation and various discomfort, what this sense of discomfort had also can involve gastrointestinal tract, cervical region, tooth and back etc.
The reason that causes coronary heart disease mainly contains following three kinds:
1, coronary atherosclerosis: be modal stenosis coronary artery disease, the particularly flesh wall atherosclerosis that coronary artery props up outward.
2, coronary vasospasm: for many years, this problem of reason whether academia is ischemic heart desease round coronary vasospasm is always argued.Someone studies discovery to cardiac sudden death case, and the sickness rate of its coronary artery thrombosis is only 30%, also only accounts for 50%, therefore think to have considerable part case at least because coronary vasospasm causes in latter 12 hours of outbreak in dead patient.In recent years, due to carrying out of angiocardiography technology, confirmed that coronary vasospasm can cause angina pectoris and myocardial infarction.
3, struvite coronary stricture; Coronary artery inflammation can cause coronary stricture, even entirely shuts and causes ischemic heart desease, and such as polyarteritis nodosa, giant cell arteritis, Wegener granulomatosis etc. all can be involved coronary artery.In addition, syphilitic aortitis also can cause stenosis of coronary orifice, but all more rare.
The major clinical types of coronary heart disease has:
1. conceal type or Asymptomatic coronary artery disease are asymptomatic, but have the ECG change of myocardial ischemia.Cardiac muscle inorganization form changes.
2. angina pectoris has ictal retrosternal pain, by momentary deficiency myocardial blood supply is caused.Many inorganizations of cardiac muscle form changes.
3. myocardial infarction serious symptom, is type the most serious in coronary heart disease, and case fatality rate is higher.
At present, the traditional Chinese medical science, for the treatment of coronary heart disease, clinically according to different syndromes, has various method for the treatment of, at present adopts blood circulation promoting and blood stasis dispelling, aromatic herbs activating YANG, the Therapeutic Method such as a surname's numbness, nourishing YIN for suppressing the hyperactive YANG, supplementing QI and nourishing YIN activate yang more.Especially activating blood and removing stasis Method, this method is applicable to the coronary heart disease person that belongs to stagnation of heart-blood, and common uncomfortable in chest, pained, pain is fixed, pain as being stabbed, purplish tongue, or there is petechia ecchymosis in Sublingual, and deep and stringy pulse or string are puckery, take this method for the treatment of, can dredge heart arteries and veins, the dissipation stasis of blood is stagnant, pained stopping.Although domestic Cardiological expert therapeutic scheme is more, mostly exist therapeutic effect undesirable, can not effect a radical cure, the shortcoming such as cost is high, therapeutic process is complicated.
Summary of the invention
For above-mentioned the deficiencies in the prior art, the invention provides a kind of pharmaceutical preparation for the treatment of coronary heart disease, it has special efficacy to coronary heart disease, has that safe and effective, instant effect, effect are lasting, a treating both the principal and secondary aspects of a disease, low cost and other advantages.
The present invention is achieved by the following technical solutions:
Treat a pharmaceutical preparation for coronary heart disease, formed by the crude drug of following weight portion: 20～30 parts of Rhizoma Polygonati Odorati, 10～15 parts of Fructus Corni, 10～15 parts of Ramulus Uncariae Cum Uncis, 5～8 parts of Semen Ziziphi Spinosae (parched)s, 5～8 parts of Radix Platycodoniss, 20～30 parts of Radix Adenophorae (Radix Glehniae), 30～40 parts of Radix Notoginseng, 25～35 parts of Rhizoma Chuanxiongs, 15～30 parts of Radix Salviae Miltiorrhizaes, 10～15 parts, Radix Rehmanniae Preparata, 10～20 parts, Radix Glycyrrhizae, 10～20 parts of the Radix Paeoniae Albas, 5～15 parts of Rhizoma Imperataes, 20～35 parts of Sanguis Draxonis, 15～25 parts of Herba Asaris, 5～20 parts of Herba Euphorbiae Humifusaes.
Preferably, formed by the crude drug of following weight portion: 25 parts of Rhizoma Polygonati Odorati, 13 parts of Fructus Corni, 13 parts of Ramulus Uncariae Cum Uncis, 6 parts of Semen Ziziphi Spinosae (parched)s, 6 parts of Radix Platycodoniss, 25 parts of Radix Adenophorae (Radix Glehniae), 35 parts of Radix Notoginseng, 30 parts of Rhizoma Chuanxiongs, 25 parts of Radix Salviae Miltiorrhizaes, 13 parts, Radix Rehmanniae Preparata, 15 parts, Radix Glycyrrhizae, 15 parts of the Radix Paeoniae Albas, 10 parts of Rhizoma Imperataes, 25 parts of Sanguis Draxonis, 20 parts of Herba Asaris, 15 parts of Herba Euphorbiae Humifusaes.
The dosage form of described pharmaceutical preparation is any in the watered pill, honeyed pill, tablet, powder, capsule, and taking capsule as example, preparation method is: get each crude drug, dry porphyrize powder, crosses 300 mesh sieves, packs capsule into No. 1, to obtain final product, and every containing crude drug 0.5 ɡ left and right.
Usage and consumption: oral, every day three times, one after each meal, each 1g left and right (2 capsules), 10 days is a course for the treatment of.Take effect a general course for the treatment of, and be clearly better or rehabilitation 2～3 courses for the treatment of.
Side effect and contraindication: through clinical observation on the therapeutic effect, patient occurs without obvious toxic-side effects; Anemia of pregnant woman and allergic constitution patient forbidding.
The pharmaceutical preparation for the treatment of coronary heart disease of the present invention, prescription has been given prominence to the feature of theory of Chinese medical science in therapeutic process, within 10 days, is a course for the treatment of, and 1～5 day takes effect, and be clearly better or rehabilitation 2～3 courses for the treatment of.Chinese medicine preparation of the present invention has the following advantages: be 1, natural Chinese medicines, toxic and side effects is little, therapeutical effect uniqueness.2, instant effect, determined curative effect, through clinical 600 many cases patients' application verification, effective percentage can reach 96.6%.
Detailed description of the invention
Below in conjunction with embodiment and case, the present invention is further illustrated.
The pharmaceutical preparation of embodiment 1 preparation treatment coronary heart disease
Formula is: 25 grams of Rhizoma Polygonati Odorati, 13 grams of Fructus Corni, 13 grams of Ramulus Uncariae Cum Uncis, 6 grams of Semen Ziziphi Spinosae (parched)s, 6 grams of Radix Platycodoniss, 25 grams of Radix Adenophorae (Radix Glehniae), 35 grams of Radix Notoginseng, 30 grams of Rhizoma Chuanxiongs, 25 grams of Radix Salviae Miltiorrhizaes, 13 grams, Radix Rehmanniae Preparata, 15 grams, Radix Glycyrrhizae, 15 grams of the Radix Paeoniae Albas, 10 grams of Rhizoma Imperataes, 25 grams of Sanguis Draxonis, 20 grams of Herba Asaris, 15 grams of Herba Euphorbiae Humifusaes.
Preparation method is: get each crude drug, dry porphyrize powder, crosses 300 mesh sieves, packs capsule into No. 1, to obtain final product.
Usage and consumption: oral, every day three times, one after each meal, each 2 10 days is a course for the treatment of.
The pharmaceutical preparation of embodiment 2 preparation treatment coronary heart disease
Formula is: 22 grams of Rhizoma Polygonati Odorati, 12 grams of Fructus Corni, 14 grams of Ramulus Uncariae Cum Uncis, 7 grams of Semen Ziziphi Spinosae (parched)s, 6 grams of Radix Platycodoniss, 22 grams of Radix Adenophorae (Radix Glehniae), 38 grams of Radix Notoginseng, 32 grams of Rhizoma Chuanxiongs, 20 grams of Radix Salviae Miltiorrhizaes, 12 grams, Radix Rehmanniae Preparata, 18 grams, Radix Glycyrrhizae, 18 grams of the Radix Paeoniae Albas, 8 grams of Rhizoma Imperataes, 22 grams of Sanguis Draxonis, 22 grams of Herba Asaris, 10 grams of Herba Euphorbiae Humifusaes.
Preparation method is: get each crude drug, dry porphyrize powder, crosses 300 mesh sieves, packs capsule into No. 1, to obtain final product.
Usage and consumption: oral, every day three times, one after each meal, each 2 10 days is a course for the treatment of.
The pharmaceutical preparation of embodiment 3 preparation treatment coronary heart disease
Formula is: 28 grams of Rhizoma Polygonati Odorati, 14 grams of Fructus Corni, 12 grams of Ramulus Uncariae Cum Uncis, 6 grams of Semen Ziziphi Spinosae (parched)s, 7 grams of Radix Platycodoniss, 28 grams of Radix Adenophorae (Radix Glehniae), 32 grams of Radix Notoginseng, 28 grams of Rhizoma Chuanxiongs, 28 grams of Radix Salviae Miltiorrhizaes, 14 grams, Radix Rehmanniae Preparata, 12 grams, Radix Glycyrrhizae, 12 grams of the Radix Paeoniae Albas, 13 grams of Rhizoma Imperataes, 30 grams of Sanguis Draxonis, 18 grams of Herba Asaris, 18 grams of Herba Euphorbiae Humifusaes.
Preparation method is: get each crude drug, dry porphyrize powder, crosses 300 mesh sieves, packs capsule into No. 1, to obtain final product.
Usage and consumption: oral, every day three times, one after each meal, each 2 10 days is a course for the treatment of.
The pharmaceutical preparation of embodiment 4 preparation treatment coronary heart disease
Formula is: 20 grams of Rhizoma Polygonati Odorati, 15 grams of Fructus Corni, 10 grams of Ramulus Uncariae Cum Uncis, 8 grams of Semen Ziziphi Spinosae (parched)s, 5 grams of Radix Platycodoniss, 30 grams of Radix Adenophorae (Radix Glehniae), 30 grams of Radix Notoginseng, 35 grams of Rhizoma Chuanxiongs, 15 grams of Radix Salviae Miltiorrhizaes, 15 grams, Radix Rehmanniae Preparata, 10 grams, Radix Glycyrrhizae, 20 grams of the Radix Paeoniae Albas, 5 grams of Rhizoma Imperataes, 35 grams of Sanguis Draxonis, 15 grams of Herba Asaris, 20 grams of Herba Euphorbiae Humifusaes.
Preparation method is: get each crude drug, dry porphyrize powder, crosses 300 mesh sieves, packs capsule into No. 1, to obtain final product.
Usage and consumption: oral, every day three times, one after each meal, each 2 10 days is a course for the treatment of.
The pharmaceutical preparation of embodiment 5 preparation treatment coronary heart disease
Formula is: 30 grams of Rhizoma Polygonati Odorati, 10 grams of Fructus Corni, 15 grams of Ramulus Uncariae Cum Uncis, 5 grams of Semen Ziziphi Spinosae (parched)s, 8 grams of Radix Platycodoniss, 20 grams of Radix Adenophorae (Radix Glehniae), 40 grams of Radix Notoginseng, 25 grams of Rhizoma Chuanxiongs, 30 grams of Radix Salviae Miltiorrhizaes, 10 grams, Radix Rehmanniae Preparata, 20 grams, Radix Glycyrrhizae, 10 grams of the Radix Paeoniae Albas, 15 grams of Rhizoma Imperataes, 20 grams of Sanguis Draxonis, 25 grams of Herba Asaris, 5 grams of Herba Euphorbiae Humifusaes.
Preparation method is: get each crude drug, dry porphyrize powder, crosses 300 mesh sieves, packs capsule into No. 1, to obtain final product.
Usage and consumption: oral, every day three times, one after each meal, each 2 10 days is a course for the treatment of.
Clinical data:
1, data:
Case-data: select in May, 2004～2012 to there are complete outpatient service data and inpatient 1256 examples year April, be divided at random treatment group 644 examples, matched group 612 examples.The treatment group age is at 45～75 years old, the course of disease 2～13 years.The matched group age is at 46～74 years old, the course of disease 1.5～13 years.Men and women's ratio and the course of disease are through X 2 test (P > 0.05) not statistically significant.
2, Therapeutic Method: the capsule treatment that treatment group is prepared with embodiment 1,3 oral meals of every natural gift, each 2 10 days is a course for the treatment of.The oral isosorbide dinitrate 10 ㎎ Tid of matched group, the heart 4 Tid that can relax.Treat observe the curative effect after three courses for the treatment of.
3, evaluation criterion:
Cure: ECG ST section recovers normal, pain, feel sick, the transference cure such as vomiting.
Take a turn for the better: ECG T wave recovers normal or low flat by being inverted, and pain greatly alleviates, feel sick, the symptom such as vomiting slightly or substantially disappears.
Invalid: electrocardiogram is without significant change, and symptom is without significant change.
4, statistical method: two groups clinical in X 2 test, and between two groups, relatively, RIDUT checks, and result is as shown in table 1.
Table 1. liang group cure rate synopsis
Note: P<0.001.
4, side effect and contraindication:
Side effect: through the clinical observation on the therapeutic effect of 20 years, patient occurred without obvious toxic-side effects.
Contraindication: anemia of pregnant woman and allergic constitution patient forbidding.
Model case:
Case 1: Tan, female, 52 years old, uncomfortable in chest, breathe hard, precordialgia, activity postemphasis, time and with nausea and vomiting, often there is angina pectoris attacks, examine as coronary heart disease.Take the capsule of embodiment 1,3 oral meals of every natural gift, each 2 10 days is a course for the treatment of.After about one week, angina pectoris is controlled, and takes after three courses for the treatment of, recovers normal, with examining half a year, without recurrence.
Case 2: beam so-and-so, man, 48 years old, suffer from repeated relapsing chest pain 8 years, with insomnia and dreamful sleep, pain when outbreak nausea and vomiting.Examined angina pectoris, medication treatment effect is not good enough throughout the year.After change the capsule of taking embodiment 1 into, 3 oral meals of every natural gift, each 2 10 days is a course for the treatment of.Remission after the course for the treatment of, after three courses for the treatment of, symptom disappears completely, continues to take and consolidates curative effect two courses for the treatment of, with examining not recurrence in 2 years.
Case 3: what certain, female, 39 years old, suffer from repeated relapsing angina pectoris 3 years, electrocardio diagram: cardiac muscle is tired, " T " ripple is inverted.Examined as coronary heart disease, take western medicine throughout the year, effect is not good enough.After the capsule treatment of taking embodiment 1 (3 oral meals of every natural gift, each 2 10 days is a course for the treatment of), remission after the course for the treatment of, after three courses for the treatment of, pain disappears, and consolidates curative effect three courses for the treatment of of continuing to take medicine, check electrocardiogram is clearly better, with examining 2 years without recurrence.
Claims (6)
1. treat the pharmaceutical preparation of coronary heart disease for one kind, it is characterized in that, formed by the crude drug of following weight portion: 20～30 parts of Rhizoma Polygonati Odorati, 10～15 parts of Fructus Corni, 10～15 parts of Ramulus Uncariae Cum Uncis, 5～8 parts of Semen Ziziphi Spinosae (parched)s, 5～8 parts of Radix Platycodoniss, 20～30 parts of Radix Adenophorae (Radix Glehniae), 30～40 parts of Radix Notoginseng, 25～35 parts of Rhizoma Chuanxiongs, 15～30 parts of Radix Salviae Miltiorrhizaes, 10～15 parts, Radix Rehmanniae Preparata, 10～20 parts, Radix Glycyrrhizae, 10～20 parts of the Radix Paeoniae Albas, 5～15 parts of Rhizoma Imperataes, 20～35 parts of Sanguis Draxonis, 15～25 parts of Herba Asaris, 5～20 parts of Herba Euphorbiae Humifusaes.
2. according to a kind of pharmaceutical preparation for the treatment of coronary heart disease described in claim 1, it is characterized in that, formed by the crude drug of following weight portion: 25 parts of Rhizoma Polygonati Odorati, 13 parts of Fructus Corni, 13 parts of Ramulus Uncariae Cum Uncis, 6 parts of Semen Ziziphi Spinosae (parched)s, 6 parts of Radix Platycodoniss, 25 parts of Radix Adenophorae (Radix Glehniae), 35 parts of Radix Notoginseng, 30 parts of Rhizoma Chuanxiongs, 25 parts of Radix Salviae Miltiorrhizaes, 13 parts, Radix Rehmanniae Preparata, 15 parts, Radix Glycyrrhizae, 15 parts of the Radix Paeoniae Albas, 10 parts of Rhizoma Imperataes, 25 parts of Sanguis Draxonis, 20 parts of Herba Asaris, 15 parts of Herba Euphorbiae Humifusaes.
3. according to a kind of pharmaceutical preparation for the treatment of coronary heart disease described in claim 1, it is characterized in that, formed by the crude drug of following weight portion: 22 parts of Rhizoma Polygonati Odorati, 12 parts of Fructus Corni, 14 parts of Ramulus Uncariae Cum Uncis, 7 parts of Semen Ziziphi Spinosae (parched)s, 6 parts of Radix Platycodoniss, 22 parts of Radix Adenophorae (Radix Glehniae), 38 parts of Radix Notoginseng, 32 parts of Rhizoma Chuanxiongs, 20 parts of Radix Salviae Miltiorrhizaes, 12 parts, Radix Rehmanniae Preparata, 18 parts, Radix Glycyrrhizae, 18 parts of the Radix Paeoniae Albas, 8 parts of Rhizoma Imperataes, 22 parts of Sanguis Draxonis, 22 parts of Herba Asaris, 10 parts of Herba Euphorbiae Humifusaes.
4. according to a kind of pharmaceutical preparation for the treatment of coronary heart disease described in claim 1, it is characterized in that, formed by the crude drug of following weight portion: 28 parts of Rhizoma Polygonati Odorati, 14 parts of Fructus Corni, 12 parts of Ramulus Uncariae Cum Uncis, 6 parts of Semen Ziziphi Spinosae (parched)s, 7 parts of Radix Platycodoniss, 28 parts of Radix Adenophorae (Radix Glehniae), 32 parts of Radix Notoginseng, 28 parts of Rhizoma Chuanxiongs, 28 parts of Radix Salviae Miltiorrhizaes, 14 parts, Radix Rehmanniae Preparata, 12 parts, Radix Glycyrrhizae, 12 parts of the Radix Paeoniae Albas, 13 parts of Rhizoma Imperataes, 30 parts of Sanguis Draxonis, 18 parts of Herba Asaris, 18 parts of Herba Euphorbiae Humifusaes.
5. according to a kind of pharmaceutical preparation for the treatment of coronary heart disease one of claim 1～4 Suo Shu, it is characterized in that: the dosage form of described pharmaceutical preparation is any in the watered pill, honeyed pill, tablet, powder, capsule.
6. the preparation method of a kind of pharmaceutical preparation for the treatment of coronary heart disease described in one of claim 1～4, is characterized in that: get each crude drug, dry porphyrize powder, crosses 300 mesh sieves, packs capsule into No. 1, to obtain final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310076846.9A CN103127413B (en) | 2013-03-11 | 2013-03-11 | Pharmaceutical preparation for treating coronary diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310076846.9A CN103127413B (en) | 2013-03-11 | 2013-03-11 | Pharmaceutical preparation for treating coronary diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103127413A CN103127413A (en) | 2013-06-05 |
| CN103127413B true CN103127413B (en) | 2014-11-26 |
Family
ID=48488283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310076846.9A Expired - Fee Related CN103127413B (en) | 2013-03-11 | 2013-03-11 | Pharmaceutical preparation for treating coronary diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103127413B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105168855A (en) * | 2015-09-22 | 2015-12-23 | 禤燕华 | Traditional Chinese medicine composition for treating angina pectoris and preparation method of traditional Chinese medicine composition |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1124153C (en) * | 2001-08-31 | 2003-10-15 | 石家庄以岭药业股份有限公司 | Medicinal composition for restoring cardiac collaterals and its application |
| CN100584372C (en) * | 2006-09-12 | 2010-01-27 | 解安兑 | External use traditional Chinese medicine ointment for treating heart diseases |
| CN102526608B (en) * | 2011-09-11 | 2013-08-14 | 张秋兰 | Preparation method of traditional Chinese medicine for treating heart blood stasis type palpitation |
| CN102302740B (en) * | 2011-09-11 | 2012-09-26 | 吕振修 | Preparation method of traditional Chinese medicine used for treating thoracic obstructions caused by yin deficiency of heart and kidney |
| CN102614474A (en) * | 2012-05-03 | 2012-08-01 | 侯安会 | Traditional Chinese medicine for treating coronary heart disease and preparation method thereof |
-
2013
- 2013-03-11 CN CN201310076846.9A patent/CN103127413B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103127413A (en) | 2013-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100382839C (en) | Chinese-medicinal composition for treating coronary heart disease | |
| CN1985965A (en) | Medicine for treating coronary heart disease and cerebral thrombus and its preparing method | |
| CN101612349B (en) | Medicine for treating coronary heart disease | |
| CN102512552B (en) | Traditional Chinese medicine composition for treating exogenous fever | |
| CN101966299B (en) | Medicament for treating wind-caused dizziness | |
| CN101816712B (en) | Chinese medicinal composition for treating trigeminal neuralgia | |
| CN103223059A (en) | Traditional Chinese medicine for treating recurrent oral ulcer | |
| CN102552520B (en) | Blood circulation-promoting and pain-stopping medicament and preparation process and application thereof | |
| CN102836338B (en) | Chinese medicament for treating cardia-cerebrovascular diseases | |
| CN103127413B (en) | Pharmaceutical preparation for treating coronary diseases | |
| CN103520272B (en) | Drug for treating coronary disease and stenocardia | |
| CN102908391A (en) | Chinese medicinal composition for treating dermatosis and preparation method and application thereof | |
| CN102579804B (en) | Chinese medicine for treating stenocardia | |
| CN101502597B (en) | Medicament for treating stomachache and preparation method thereof | |
| CN103191326B (en) | Medicine preparation for treating coronary heart diseases | |
| CN104001026A (en) | Medicine for treating myocardial ischemia | |
| CN103316226B (en) | Traditional Chinese medicine composition for treating coronary heart disease | |
| CN103212041A (en) | Chinese medicinal composition treating coronary heart disease | |
| CN103028088B (en) | Traditional Chinese medicine composition for treating coronary heart disease and angina | |
| CN105250861A (en) | Compound preparation for treating coronary heart disease | |
| CN102861241B (en) | Traditional Chinese medicine qi-reinforcing and stasis-removing soup for treating acute myocardial infarction | |
| CN104800574A (en) | Chinese drug preparation for treating coronary heart disease | |
| CN102293891A (en) | Chinese medicine for treating cardiovascular disease and preparation method thereof | |
| CN106237069A (en) | A kind of Chinese medicine formula treating coronary heart disease | |
| CN106177422A (en) | A kind of Chinese medicine formula of warming YANG to expel cold |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141126 Termination date: 20150311 |
|
| EXPY | Termination of patent right or utility model |